Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm-Reference-Cited by-同舟云学术

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm

Published:2017-03 Issue:3 Volume:28 Page:673-675
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Haddox C.L.,Shenoy N.,Shah K.K.,Kao J.C.,Jain S.,Halfdanarson T.R.,Wijdicks E.F.,Goetz M.P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/3/673/11203365/mdw655.pdf

Reference7 articles.

1. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

2. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

3. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

4. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1;Sul;Oncologist,2016

5. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort;Chow;J Clin Oncol,2016

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action;Brain Sciences;2024-07-29

2. Pembrolizumab-induced necrotizing diaphragmatic myositis;Journal of Mechanical Ventilation;2024-06-15

3. Unsuccessful Weaning From Mechanical Ventilation in a Patient With An Immune-Mediated Necrotizing Myopathy;CHEST;2024-06

4. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

5. Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti–PD-1 Immune Checkpoint Inhibitor Cancer Therapy;The Journal of Immunology;2024-03-01